Celldex Therapeutics Inc. (CLDX) had a rough trading day for Monday April 15 as shares tumbled 5.06%, or a loss of $-0.22 per share, to close at $4.13. After opening the day at $4.30, shares of Celldex Therapeutics Inc. traded as high as $4.38 and as low as $4.10. Volume was 312,849 shares over 1,308 trades, against an average daily volume of n/a shares and a total float of 12.44 million.
As a result of the decline, Celldex Therapeutics Inc. now has a market cap of $51.38 million. In the last year, shares of Celldex Therapeutics Inc. have traded between a range of $15.90 and $2.75, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140, and CDX-3379.
Celldex Therapeutics Inc. is based out of Hampton, NJ and has some 135 employees. Its CEO is Anthony S. Marucci.